Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Immunological Reviews|June 2, 2021
Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironmentMélanie Desbois, Yulei WangBulletin Du Cancer|January 23, 2015
[Breaking immune tolerance in cancer]Mélanie Desbois, Stéphane Champiat, Nathalie ChaputFrontiers in Immunology|December 28, 2012
Natural killer cells in non-hematopoietic malignanciesMélanie Desbois, Sylvie Rusakiewicz, Clara Locher, et al.Journal for Immunotherapy of Cancer|August 14, 2020
Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effectsJulia Delahousse, Charles Skarbek, Mélanie Desbois, et al.Journal for Immunotherapy of Cancer|June 14, 2020
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatmentMélanie Desbois, Coralie Béal, Mélinda Charrier, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 25, 2016
IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 AntagonistsMélanie Desbois, Pauline Le Vu, Clélia Coutzac, et al.Oncoimmunology|March 26, 2013
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR<sup>+</sup> NK cell levels correlate with disease outcomeNathalie Chaput, Caroline Flament, Clara Locher, et al.Cancer Research|July 5, 2011
IL-18 induces PD-1-dependent immunosuppression in cancerMagali Terme, Evelyn Ullrich, Laetitia Aymeric, et al.Cancer Cell|May 7, 2021
Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancerMilena Hornburg, Mélanie Desbois, Shan Lu, et al.Cancer Immunology Research|May 22, 2025
IGM-7354, an immunocytokine with IL-15 fused to an anti-PD-L1 IgM, induces NK and CD8+ T cell-mediated cytotoxicity of PD-L1 positive tumor cellsMélanie Desbois, Thierry Giffon, Poonam Yakkundi, et al.Pageof 2